Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones
Series C financing co-led by Double Point Ventures and DCVC Bio Proceeds to support the clinical development of VivoVec™ derived in vivo CAR T cells SEATTLE, WA, January 14, 2025— Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing […]